ImmunoGen Shares Up 15% Premarket After Co Announced Sunday, ELAHERE Demonstrated 35% Reduction In The Risk Of Disease Progression Or Death Vs Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
Portfolio Pulse from Charles Gross
ImmunoGen shares rose 15% premarket after the company announced that ELAHERE demonstrated a 35% reduction in the risk of disease progression or death compared to chemotherapy in FRα-positive platinum-resistant ovarian cancer.
June 05, 2023 | 9:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunoGen's stock price increased by 15% premarket after announcing positive results for ELAHERE in reducing the risk of disease progression or death in ovarian cancer patients.
The positive results from ELAHERE's clinical trial demonstrate the potential effectiveness of the treatment in reducing the risk of disease progression or death in ovarian cancer patients. This news is likely to boost investor confidence in ImmunoGen, leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100